Eterna Therapeutics (US:ERNA) Globenewswire·2025-11-10 13:35Core Insights - Ernexa Therapeutics reported a significant reduction in operating losses, with a 44% decline year-over-year, indicating effective operational execution and financial discipline [1][11] - The company is advancing its lead program, ERNA-101, towards a first-in-human Phase 1 study in platinum-resistant ovarian cancer, expected to commence in the second half of 2026 [1][6] - Ernexa has established a partnership with Cellipont Bioservices to enhance the development of ERNA-101, alongside reporting substantial year-over-year financial performance improvements [3][4] Financial Performance - The operating loss for the three months ended September 30, 2025, decreased by $0.3 million, or 12%, from $2.3 million in the same period of 2024 to $2.0 million [11] - For the nine months ended September 30, 2025, the operating loss decreased by $5.8 million, or 44%, from $13.0 million in 2024 to $7.2 million [11] - General and administrative expenses saw a significant reduction, with a 72% decrease from $3.4 million to $1.0 million for the three-month period, primarily due to a decrease in rent and legal fees [11] Development Programs - Ernexa is utilizing synthetic, allogeneic induced mesenchymal stem cells (iMSCs) for scalable, off-the-shelf treatments, focusing on ovarian cancer and autoimmune diseases [4][8] - ERNA-101 is designed to secrete pro-inflammatory fusion cytokines and is currently in preclinical development for platinum-resistant ovarian cancer [5][9] - ERNA-201 targets inflammation and is in preclinical development for rheumatoid arthritis and other inflammatory diseases [5][9] Strategic Collaborations - The partnership with Cellipont Bioservices is a strategic move to advance ERNA-101 towards clinical trials [3][4] - A sponsored research agreement with MD Anderson Cancer Center aims to leverage MSCs' tumor-homing ability to enhance anti-tumor activity while minimizing systemic toxicity [6]